Mukherjee Biswajit, Patra Balaram, Layek Buddhadev, Mukherjee Arup
Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
Int J Nanomedicine. 2007;2(2):213-25.
The present study was designed to develop and compare acyclovir containing nano-vesicular liposomes and niosomes based on cholesterol, soya L-alpha-lecithin and nonionic surfactant, span 20. The effort was made to study in vitro whether acyclovir-loaded nanovesicles could sustain the release of the drug by increasing residence time and thus, acyclovir could reduce its dose-related systemic toxicity. There were good vesicular distributions in both of the niosomes and the liposomes. The obtained vesicles were within 1 microm and about 35% of them were within a size of 100 nm. The percentage of drug loading varied and the niosomal vesicles contained more drug as compared with the liposomes. When the in vitro drug release was compared, it was found that the liposomes released about 90% drug in 150 min whereas the drug release was just 50% from the niosomal vesicles in 200 min. Again, the niosomes showed better stability compared with the liposomes. Thus, niosome could be a better choice for intravenous delivery of acyclovir.
本研究旨在开发并比较基于胆固醇、大豆L-α-卵磷脂和非离子表面活性剂司盘20的含阿昔洛韦的纳米囊泡脂质体和非离子表面活性剂囊泡。研究了载阿昔洛韦纳米囊泡是否能通过延长驻留时间来维持药物释放,从而使阿昔洛韦降低其剂量相关的全身毒性。非离子表面活性剂囊泡和脂质体均有良好的囊泡分布。所获得的囊泡直径在1微米以内,其中约35%的囊泡大小在100纳米以内。载药量的百分比各不相同,与脂质体相比,非离子表面活性剂囊泡含有更多药物。比较体外药物释放时发现,脂质体在150分钟内释放约90%的药物,而非离子表面活性剂囊泡在200分钟内药物释放仅为50%。同样,与脂质体相比,非离子表面活性剂囊泡显示出更好的稳定性。因此,非离子表面活性剂囊泡可能是阿昔洛韦静脉给药的更好选择。